START FREE TRIAL

Broadcom Stock Drops on AI Outlook: Did Nvidia and Oracle Just Set the Trap?

AI Summary

🔒 UNLOCK AI SUMMARY WITH FREE TRIAL

START FREE TRIAL

Broadcom (NASDAQ:AVGO) just had its worst stock day in nearly a year—and the culprit was something investors were previously cheering: AI. On the surface, the company had a strong quarter. Revenue hit a record $18 billion, AI chip sales surged, and its infrastructure software business delivered steady growth. So why did the stock fall 11%? One word: expectations. The market had priced in a moonshot AI trajectory and Broadcom’s latest earnings call delivered a more earthbound message. While the company talked up its AI order backlog—$73 billion over the next 18 months—it also declined to give precise AI revenue forecasts, dodged questions on a mystery $1 billion customer, and hinted at tightening gross margins. For a stock trading at nosebleed multiples, that was enough to trigger a selloff. Let’s walk through what really happened and what it says about how Wall Street is valuing AI-driven semiconductor stocks.

AI Revenue Guidance & The Gap Between Management & Investor Expectations

Investors came into the earnings call looking for fireworks. Broadcom’s stock had already run up 75% year-to-date. Wall Street wanted more than solid execution—it wanted a new mega-customer, bigger AI numbers, and bullish revenue forecasts. What it got instead was…

Continue Reading With Our 7-Day Free Trial

ONLY $10 per month after the trial. Cancel anytime. No sponsors. No conflicts. 100% independent stock research.

Recent Articles

This “Broken” Biotech Just Forced Wall Street To Blink

Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Tesla Is Quietly Killing Its Own Cars—& What Comes Next Could Be MUCH BIGGER

For years, most investors have approached Tesla as an...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Boston Scientific (NYSE:BSX) spent the weekend putting forward what...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

For years, McCormick (NYSE:MKC) has been framed as one...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

A mid-cap biotech with the first approved therapy in...

Related Articles

This “Broken” Biotech Just Forced Wall Street To Blink

Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Tesla Is Quietly Killing Its Own Cars—& What Comes Next Could Be MUCH BIGGER

For years, most investors have approached Tesla as an...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Boston Scientific (NYSE:BSX) spent the weekend putting forward what...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

For years, McCormick (NYSE:MKC) has been framed as one...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

A mid-cap biotech with the first approved therapy in...
spot_img

Related Articles

Popular Categories

spot_imgspot_img